To complement CareFusion deal, BD buys startup with real-time, wireless manual IV drug data

Becton Dickinson ($BDX) has acquired Crisi Medical Systems for an undisclosed sum. The San Diego, CA-based startup is the only provider of real-time drug identification, dose measurement and allergy detection data for manual IV bolus injections that wirelessly populates patient electronic medical records, according to BD.

Dubbed the Intelliport system, the Crisi system was just cleared by the FDA in December and is expected to hit markets this spring. It's intended to bring some of the integrated data routinely available with preset IV infusion pumps to manual IV delivery, which includes anesthesia as well as emergency applications.

BD is no stranger to Crisi; in fact, the pair jointly developed Intelliport.

The acquisition "gives BD access to the injection safety market with a differentiated platform that we believe, when combined with our pending CareFusion acquisition, will significantly enhance our growing end-to-end IV medication safety offering," Tom Polen, BD Medical Segment president, said in a statement.

The $12.2 billion acquisition of CareFusion ($CFN) by BD is slated to close by March 31.

Vince Forlenza

On the fit between Crisi's Intelliport and the soon-to-be-acquired CareFusion, BD chairman, CEO and President Vincent Forlenza said on the latest earnings call, "This product underscores our commitment to BD's medication management franchise, and is complementary to CareFusion's smart pump and informatics platform. This represents the next wave of patient safety related products."

CareFusion markets infusion pumps and IV sets as well as automated medication dispensing and patient identification systems, ventilation and respiratory products, surgical instruments and interventional support products. It had fiscal 2014 revenues of $3.84 billion, which it expects will grow 5% to 7% in fiscal 2015. The financial details of the acquisition remain undisclosed.

- here is the release

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.